PE20061042A1 - Derivados de 5-fenilpirimidina como agentes para el tratamiento del cancer - Google Patents

Derivados de 5-fenilpirimidina como agentes para el tratamiento del cancer

Info

Publication number
PE20061042A1
PE20061042A1 PE2006000121A PE2006000121A PE20061042A1 PE 20061042 A1 PE20061042 A1 PE 20061042A1 PE 2006000121 A PE2006000121 A PE 2006000121A PE 2006000121 A PE2006000121 A PE 2006000121A PE 20061042 A1 PE20061042 A1 PE 20061042A1
Authority
PE
Peru
Prior art keywords
halogen
alkyl
cancer
treatment
phenylpyrimidine
Prior art date
Application number
PE2006000121A
Other languages
English (en)
Inventor
Joachim Rheinheimer
Thomas Grote
Barbara Nave
Anja Schwogler
Carsten Blettner
Thorsten Jabs
Frank Schieweck
Bernd Muller
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of PE20061042A1 publication Critical patent/PE20061042A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A COMPUESTOS DERIVADOS DE 5-FENILPIRIMIDINAS DE FORMULA I, DONDE X ES UN GRUPO DE FORMULA NR1R2, OR1a O SR1a; R1 Y R2 SON H, ALQUILO C1-C10, ALQUENILO C2-C6, ALQUINILO C2-C6, ENTRE OTROS; Ra1 ES HALOGENO, NITRO, CIANO, ENTRE OTROS; Y ES HALOGENO, CIANO, ALQUILO C1-C4, ALQUENILO C2-C4, ENTRE OTROS; R4 ES HALOGENO, NITROGENO, OXIGENO, ENTRE OTROS; L ES HALOGENO, NITROGENO, OXIGENO, ENTRE OTROS; n ES UN ENTERO ENTRE 0 A 5. DICHOS COMPUESTOS INHIBEN EL CRECIMIENTO Y/O LA PROGENESIS DE CELULAS TUMORALES Y SON UTILES PARA EL TRATAMIENTO DEL CANCER
PE2006000121A 2005-01-31 2006-01-30 Derivados de 5-fenilpirimidina como agentes para el tratamiento del cancer PE20061042A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05001955 2005-01-31

Publications (1)

Publication Number Publication Date
PE20061042A1 true PE20061042A1 (es) 2006-11-20

Family

ID=34933530

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000121A PE20061042A1 (es) 2005-01-31 2006-01-30 Derivados de 5-fenilpirimidina como agentes para el tratamiento del cancer

Country Status (19)

Country Link
US (1) US20080146593A1 (es)
EP (1) EP1845991A2 (es)
JP (1) JP2008528535A (es)
KR (1) KR20070104893A (es)
CN (1) CN101111250A (es)
AR (1) AR054220A1 (es)
AU (1) AU2006208621B2 (es)
BR (1) BRPI0607108A2 (es)
CA (1) CA2595958A1 (es)
EA (1) EA014098B1 (es)
IL (1) IL184375A0 (es)
MX (1) MX2007008397A (es)
NZ (1) NZ556448A (es)
PE (1) PE20061042A1 (es)
TW (1) TW200637556A (es)
UA (1) UA87895C2 (es)
UY (1) UY29352A1 (es)
WO (1) WO2006079556A2 (es)
ZA (1) ZA200707315B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2066655A2 (en) * 2006-09-07 2009-06-10 Neurosearch A/S Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
TW200836741A (en) * 2007-01-11 2008-09-16 Basf Ag 2-substituted pyrimidines I in therapy
KR100936278B1 (ko) * 2007-12-14 2010-01-13 한국생명공학연구원 단백질 포스파타제의 활성을 억제하는 피리미딘 유도체또는 이의 약학적으로 허용가능한 염을 유효성분으로함유하는 암 예방 및 치료용 조성물
EP2326627A1 (en) * 2008-08-20 2011-06-01 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
CN111065635B (zh) * 2018-01-04 2022-07-22 无锡安万生物科技有限公司 作为mth1抑制剂的新型嘧啶衍生物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006235A (en) * 1973-03-23 1977-02-01 Burroughs Wellcome Co. Treating CNS lymphoma
GB8314643D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Pyrimidine derivatives
GB9012316D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9700664D0 (en) * 1997-01-14 1997-03-05 British Tech Group Anti-cancer agents
JP4361736B2 (ja) * 2001-03-15 2009-11-11 ビーエーエスエフ ソシエタス・ヨーロピア ５−フェニルピリミジン、その製造方法、製造のための中間体および有害な菌類を防除するための使用
EP1399428A1 (en) * 2001-06-12 2004-03-24 Neurogen Corporation 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators
CN1312134C (zh) * 2001-11-19 2007-04-25 巴斯福股份公司 5－苯基嘧啶化合物、包含它们的组合物、其制备方法及其用途
US7320975B2 (en) * 2002-02-21 2008-01-22 Basf Aktiengesellschaft 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, method and intermediate products for the production and use thereof for combating noxious fungi
DE60336735D1 (de) * 2002-07-22 2011-05-26 Orchid Res Lab Ltd Neue biologischaktive molekü le
US7371758B2 (en) * 2003-03-13 2008-05-13 National Science & Technology Development Agency Antimalarial pyrimidine derivatives and methods of making and using them
EP1633728A1 (de) * 2003-05-20 2006-03-15 Basf Aktiengesellschaft 2-substituierte pyrimidine
EA200600171A1 (ru) * 2003-07-24 2006-08-25 Басф Акциенгезельшафт 3-замещенные пиримидины
ATE432077T1 (de) * 2003-09-24 2009-06-15 Wyeth Corp 5-arylpyrimidine als anti-krebs-mittel
US20050070712A1 (en) * 2003-09-26 2005-03-31 Christi Kosogof Pyrimidine derivatives as ghrelin receptor modulators
DE102004003493A1 (de) * 2004-01-23 2005-08-11 Bayer Cropscience Ag 5-Phenylpyrimidine
US20080132522A1 (en) * 2004-07-14 2008-06-05 Basf Aktiengesellschaft 2-Substituted Pyrimidines, Method for Their Production and Their Use for Controlling Pathogenic Fungi

Also Published As

Publication number Publication date
EA014098B1 (ru) 2010-08-30
EP1845991A2 (en) 2007-10-24
US20080146593A1 (en) 2008-06-19
JP2008528535A (ja) 2008-07-31
AU2006208621A1 (en) 2006-08-03
ZA200707315B (en) 2008-11-26
KR20070104893A (ko) 2007-10-29
EA200701582A1 (ru) 2008-02-28
WO2006079556A2 (en) 2006-08-03
IL184375A0 (en) 2007-10-31
WO2006079556A3 (en) 2006-09-21
UA87895C2 (en) 2009-08-25
BRPI0607108A2 (pt) 2010-03-09
MX2007008397A (es) 2007-09-07
NZ556448A (en) 2010-12-24
TW200637556A (en) 2006-11-01
CN101111250A (zh) 2008-01-23
UY29352A1 (es) 2006-08-31
CA2595958A1 (en) 2006-08-03
AU2006208621B2 (en) 2011-08-11
AR054220A1 (es) 2007-06-13

Similar Documents

Publication Publication Date Title
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
GT200300296A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
ECSP10010361A (es) Derivados de piridazinona
HN2005000212A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ECSP109953A (es) Derivados de piridazinona
NI200900190A (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal. pc33495a
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
HN2002000067A (es) Inhibidores de la rho - quinasa.
CY1113538T1 (el) Παραγωγα της 5-αμινο-2,4,7-τριοξο-3,4,7,8-τετραϋδρο-2η-πυριδο[2,3-d] πυριμιδινης και παρομοιες ενωσεις για την αγωγη του καρκινου
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
PA8680701A1 (es) Derivados de oxindol
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
UY27225A1 (es) Inhibidores de la rho-quinasa
UY28150A1 (es) Agentes terapeuticos
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
ECSP088820A (es) Síntesis de acil-amino-alquenilen-amidas utiles como antagonistas de la sustancia p.
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
HN2006042221A (es) Derivados de piridina para el tratamiento del crecimiento celular anormal
CR8749A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
ECSP066406A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ECSP088598A (es) Derivados de piridazinona
CO6351786A2 (es) Inkibidores de la cinasa map p38
ECSP077130A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de náuseas y vómitos

Legal Events

Date Code Title Description
FC Refusal